FIGURE 1. Study participation flowchart from screening to study completion, including reasons for non-randomization, discontinuation, and exclusion from the per protocol set.

*Other: Participant received second dose outside of scheduled window

PPS, per protocol set, i.e. all participants who were seronegative at baseline, received at least one dose of TAK-003 or placebo, and had no major protocol deviations

Source: Figure prepared by the authors from current study data